Envue

Executive Summary

Envue, founded in 2020 and headquartered in Yokneam, Israel, is a privately held biotechnology company developing next-generation therapeutics for serious diseases, with a focus on oncology and immunology. Leveraging a proprietary molecular platform, Envue aims to modulate immune pathways and target tumor biology through novel mechanisms of action. The company remains in the pre-clinical stage, addressing high-unmet medical needs with differentiated approaches. While specific program details are limited, Envue's strategic vision centers on creating innovative modalities that could transform treatment paradigms in immune-oncology.

Upcoming Catalysts (preview)

• H2 2026Preclinical Data Presentation at Major Conference40% success
• 2026Series A Financing Round30% success
• 2027IND-Enabling Studies Initiation50% success